Navigation Links
Stored Ovarian Tissue Needs Testing Before Re-Implantation
Date:4/24/2008

Inadequate safeguards could mean a return of cancer, study warns

THURSDAY, April 24 (HealthDay News) -- Cancer can return in patients who have been successfully treated if ovarian or testicular tissue they had stored in hope of regaining fertility is transplanted back into their bodies without it being adequately checked for cancer cells, according to a new report.

Researchers at two university hospitals in Israel, writing in the April 22 issue of Human Reproduction, then warned that most fertility centers lack the skills and technology to ensure the tissue is free of residual cancer cells.

Hundreds of cancer patients worldwide have ovarian tissue and testicular tissue frozen in the hope of being able to have children once their treatment has finished. However, it is possible for the original cancer to re-infect the body when the tissue is re-implanted.

"We think it's vitally important to raise awareness amongst cancer patients, fertility specialists, oncologists and hematologists. There are few fertility centers in the world with the expertise and the technology to run the types of tests on tissue that are needed to detect residual cancer," first author Dror Meirow, who leads the fertility preservation program at Chaim Sheba Medical Center, said in a prepared statement.

Over 10 years, Meirow and his team collected and froze several strips of tissue from 56 women about to receive chemotherapy for hematological cancers such as Hodgkin lymphoma, non-Hodgkin lymphoma and leukemia. Over the years, the strips were thawed and checked for cancer cells using the most modern methods available at the time. The results were compared with the same tests carried out on the patients' diseased tissue at the time of harvest to ensure the tests were capable of detecting cancer when it was known to be present.

Only one test ever detected minimal residual disease in ovarian tissue: modern, highly sensitive, real-time polymerase chain reaction (PCR), a test that amplifies sections of DNA to detect molecular markers that would indicate the presence of cancer cells. The authors suggested that, as methods for detecting cancer cells are improving all the time, and ovarian tissue can be stored for more than 10 years, tests to detect residual disease should be carried out just before transplantation rather than at the time of collection. To do this, it is necessary to freeze smaller pieces of ovarian tissue separately for minimal residual disease investigation.

"The next step is to inform patients about the increasing success of ovarian tissue transplantation, to continue to improve the success of ovarian tissue transplantation, but also to call on fertility centers that store ovarian tissue to look for minimal residual disease and to start freezing tissue now for future investigation," Meirow said. "All of this holds true for testicular tissue, too, although we are not so advanced in successfully removing, storing and transplanting testicular tissue as we are with ovarian tissue."

More information

The American Cancer Society has more about ovarian cancer treatment.



-- Kevin McKeever



SOURCE: European Society for Human Reproduction and Embryology, news release, April 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
2. Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store
3. Lymphatic vessel and lymph node function are restored with growth factor treatment
4. 600 Smiles Restored Thanks to the AACDCFs Give Back A Smile Program - October Marks National Domestic Violence Awareness Month
5. Scientists Develop Natural Protection for Stored Foods
6. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
7. FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
8. Specialized Care for Ovarian Cancer Improves Outcomes
9. Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers
10. Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment
11. Gleevec May Disrupt Ovarian Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
Breaking Medicine Technology: